Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I study.,Journal of Allergy and Clinical Immunology

当前位置： X-MOL 学术 › J. Allergy Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I study.
Journal of Allergy and Clinical Immunology ( IF 11.4 ) Pub Date : 2020-04-29 , DOI: 10.1016/j.jaci.2020.03.038
Zonne L M Hofman ₁ , Chantal C Clark ₂ , C Erik Hack ₃ , Steven de Maat ₂ , Coen Maas ₂

Affiliation

The oral kallikrein inhibitor ATN-249 is a candidate therapy for hereditary angioedema. We demonstrate the biological activity of this compound in plasma samples from a phase I study through investigation of ex vivo triggered contact activation.

中文翻译：